Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that the amended protocol is still under...

Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll be short and sweet. We make no prediction as for...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a client - there are a number of...

FDA Approval for Provention Bio (PRVB).

Re-cork the Champagne! We were contemplating (dreaming) about an opening price over $12, and then a drift up towards $20, sometime during 2023. But no,...

Provention Bio (PRVB) Gains 26% Last Week.

We're up 106% From Adding to the 2022 Watch List Last July. And up 26% a Week After Urging Holders to Calm Down, Let's...

He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!

Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along. Despite the 78% gain since November 17th, the...

Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital

Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval. They got...

Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...

Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings. Ardelyx ( NASDAQ: ARDX ) gained 35% Friday after the biotech reported better-than-expected financials...
Unicycive

Unicycive (UNCY) Shoots and Scores, up 40% Today!

We're up 126% Since December, and That Ain't Bad. Note: This isn't the end, it's just the beginning. LIVE QUOTE Adding Unicycive (UNCY) $0.75 to...

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

Eric Sprott, on Who is the Next Eric Sprott! To say Eric Sprott has left a legendary mark on the world of mining investment would...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...